Subcutaneous DMPA (DMPA-SC) updates
As countries work to expand contraceptive options, self-injectable subcutaneous DMPA (DMPA-SC) offers a promising way to reduce unmet need and broaden access through multiple delivery channels.
Sign up for DMPA-SC updates
Led by PATH in partnership with the Africa Resource Centre, Metrics for Management, Solina Centre for International Development and Research, and Health Systems Insight, the Advancing Injectable Markets for Sustainability (AIMS) project is dedicated to improving women’s choice and enduring access to injectable contraception. AIMS is creating a sustainable market for DMPA-SC and self-injection, ensuring balanced supply and demand with robust public- and private-sector access to contraceptive injectables for women living in low- and middle-income countries.
Subscribe to receive periodic updates on the global efforts of AIMS and its partners to expand contraceptive access and options. For more information, please visit the DMPA-SC Resource Library or email FPoptions@path.org.
